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Abstract: More than one year has passed since the first cases of coronavirus disease 2019 (COVID-19)
caused by severe acute respiratory syndrome (SARS)-CoV-2 coronavirus were reported in Wuhan
(China), rapidly evolving into a global pandemic. This infectious disease has become a major public
health challenge in the world. Unfortunately, to date, no specific antivirals have been proven to
be effective against COVID-19, and although a few vaccines are available, the mortality rate is not
decreasing but is still increasing. One therapeutic strategy has been focused on infection prevention
and control measures. In this regard, the use of nutraceutical supports may play a role against
some aspect of the infection, particularly the inflammatory state and the immune system function
of patients, thus representing a strategy to control the worst outcomes of this pandemic. For this
reason, we performed an overview including meta-analyses and systematic reviews to assess the
association among melatonin, vitamin C, vitamin D, zinc supplementation and inflammatory markers
using three databases, namely, MEDLINE, PubMed Central and the Cochrane Library of Systematic
Reviews. According to the evidence available, an intake of 50,000 IU/month of vitamin D showed
efficacy in CRP. An amount of 1 to 2 g per day of vitamin C demonstrated efficacy both in CRP
and endothelial function, and a dosage of melatonin ranging from 5 to 25 mg /day showed good
evidence of efficacy in CRP, TNF and IL6. A dose of 50 mg/day of elemental zinc supplementation
showed positive results in CRP. Based on the data reported in this review, the public health system
could consider whether it is possible to supplement the current limited preventive measures through
targeted nutraceutical large-scale administration.
Keywords: COVID-19; SARS-CoV-2; overview; systematic review; vitamin D; vitamin C; melatonin;
zinc; inflammation; nutraceuticals
1. Introduction
The coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, has rapidly spread
worldwide. The clinical spectrum of SARS-CoV-2 severity may range from asymptomatic
to severe conditions, including acute respiratory distress syndrome and sometimes leading
to multiorgan failure. For most people, a piece of important information is to know how to
strengthen the immune system to prevent SARS-CoV-2 infection to avoid the next waves of
the deadly COVID-19 pandemic [1]. It is well known that the presence of chronic diseases
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may exacerbate the inflammatory response induced by coronavirus disease, increasing the
risk of severe disease and mortality. In this respect, systemic inflammation developing
in people with non-communicable diseases, such as diabetes, tends to exacerbate the
respiratory symptoms of infection [2]. Additionally, obesity and central adiposity represent
important risk factors for complications of COVID-19, especially in patients with impaired
heart and lung function [3]. Furthermore, the vascular damage frequent in diabetic patients
and people with hypertension increases the risk of these individuals being affected by
COVID-19 thrombotic complications. The latest report issued by WHO mentioned more
than 96 million confirmed cases and more than two million deaths worldwide [4]. To
reduce the risk of transmission of SARS-CoV-2, several preventive measures have been
advised for general public health, including hand and respiratory hygiene and safe food
practices (concerning raw animal products) to reduce the risk of transmission of SARS-
CoV-2 [5]. The use of both a correct life-style and nutraceutical supports of proven efficacy
may play a role against some aspect of the infection, thus representing a strategy to control
this epidemic. In the current situation, it is urgent to propose preventive health measures
to reduce the risk of COVID-19 infection in addition to an adequate vaccine diffusion
and/or effective antiviral drugs. In the COVID-19 pandemic, the importance of adequate
nutrition and eating habits has been widely emphasized, not only to reduce the impact of
the widely diffused non-communicable diseases that may cause more severe infections (e.g.,
diabetes and obesity) but also as a way to regulate the inflammatory state of patients. In
fact, underestimating the importance of nutrition for COVID-19 patients will significantly
affect the prognosis of these subjects [6]. Vitamins C and D and trace elements, including
zinc [7], may play a fundamental role in disease susceptibility and maintaining immune
system function [8]. In fact, COVID-19 is characterized by high levels of inflammatory
markers, including C-reactive protein (CRP) and increased levels of inflammatory cytokines
and chemokines [9,10]. Any nutritional/nutraceutical approach potentially useful to
regulate immune function may consequently be beneficial both in the early phase, when an
adequate immune reaction is fundamental, and in case of later cytokine storm, when the
hyper-reactive immunity may be detrimental. This overview aims to analyze the current
knowledge from systematic reviews of the relationship between nutraceutical supports
and the reduction in inflammatory response to formulate clinical recommendations and
highlight directions for future research during the COVID-19 pandemic. The influence of
nutraceutical compounds on inflammatory markers will be addressed.
2. Materials and Methods
2.1. Eligibility Criteria
All meta-analyses and systematic reviews (SRs) regarding the association among
melatonin, vitamin C, vitamin D, zinc supplementation and inflammatory markers were
eligible for this overview.
2.2. Search Methods
On 22 September 2020, at 10:06 a.m. (GMT -5, Bethesta, MA, USA), a literature
search was performed, regarding MEDLINE, PubMed Central and the Cochrane Library of
Systematic Reviews (CLSR) and using the following search strings.
2.2.1. Melatonin
(“melatonin” [MeSH Terms] OR “melatonin” [All Fields] OR “melatonin s” [All Fields]
OR “melatonin” [All Fields] OR “melatonins” [ All Fields]) AND (“inflammatories” [All
Fields] OR “inflammatory” [All Fields] OR (“inflammation” [MeSH Terms] OR “inflam-
mation” [All Fields] OR “inflammations” [All Fields] OR “inflammation s “[All Fields])
OR” TNF “[All Fields] OR (“ interleukine “[All Fields] OR” interleukines “[All Fields] OR”
interleukins “[MeSH Terms] OR” interleukins “[All Fields] OR” interleukin “[All Fields])
OR (“ cytokin “[All Fields] OR” cytokine s “[All Fields] OR” cytokines “[MeSH Terms] OR”
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cytokines “[All Fields] OR” cytokine “[All Fields] OR” cytokinic “[All Fields] OR” cytokins
“[All Fields])).
2.2.2. Vitamin C
(“ascorbic acid” [MeSH Terms] OR (“ascorbic” [All Fields] AND “acid” [All Fields])
OR “ascorbic acid” [All Fields] OR “ vitamin c “[All Fields] OR (“ ascorbate “[All Fields]
OR” ascorbates “[All Fields] OR” ascorbic “[All Fields]) OR (“ ascorbate “[All Fields] OR”
ascorbates “[All Fields] OR “ascorbic” [All Fields])) AND (“inflammation” [MeSH Terms]
OR “inflammation” [All Fields] OR “inflammations” [All Fields] OR “inflammation s” [All
Fields] OR (“inflammatories” [ All Fields] OR “inflammatory” [All Fields]) OR “TNF” [All
Fields] OR (“interleukine” [All Fields] OR “interleukines” [All Fields] OR “interleukins”
[MeSH Terms] OR “interleukins” [ All Fields] OR “interleukin” [All Fields]) OR (“cytokin”
[All Fields] OR “cytokine s” [All Fields] OR “cytokines” [MeSH Terms] OR “cytokines” [All
Fields] OR “cytokine” [All Fields] OR “cytokinic” [All Fields] OR “cytokins” [All Fields])).
2.2.3. Vitamin D
(“vitamin d” [MeSH Terms] OR “vitamin d” [All Fields] OR “ergocalciferols” [MeSH
Terms] OR “ergocalciferols” [All Fields] OR (“ergocalciferols “[MeSH Terms] OR” ergocal-
ciferols “[All Fields] OR” ergocalciferol “[All Fields]) OR (“ cholecalciferol “[MeSH Terms]
OR” cholecalciferol “[All Fields] OR” cholecalciferols “[All Fields] OR” colecalciferol “[All
Fields]) OR (“ calcitriol “[MeSH Terms] OR” calcitriol “[All Fields] OR” calcitriols “[All
Fields])) AND (“ inflammation “[MeSH Terms] OR” inflammation “[All Fields] OR “inflam-
mations” [All Fields] OR “inflammation s” [All Fields] OR (“inflammatories” [All Fields]
OR “inflammatory” [All Fields]) OR “TNF” [All Fields] OR (“interleukine” [All Fields]
OR “interleukines” [All Fields] OR “interleukins” [MeSH Terms] OR “interleukins” [All Fi
elds] OR “interleukin” [All Fields]) OR (“cytokin” [All Fields] OR “cytokine s” [All Fields]
OR “cytokines” [MeSH Terms] OR “cytokines” [All Fields] OR “cytokine” [ All Fields] OR
“cytokinic” [All Fields] OR “cytokins” [All Fields])).
2.2.4. Zinc
(“zinc” [MeSH Terms] OR “zinc” [All Fields]) AND (“inflammation” [MeSH Terms]
OR “inflammation” [All Fields] OR “inflammations” [All Fields] OR “inflammation s” [All
Fields] OR (“inflammatories” [All Fields] OR “inflammatory” [All Fields]) OR “TNF” [All
Fields] OR (“interleukine” [All Fields] OR “ interleukines “[All Fields] OR” interleukins
“[MeSH Terms] OR” interleukins “[All Fields] OR” interleukin “[All Fields]) OR (“ cytokin
“[All Fields] OR” cytokine s “[All Fields] OR “cytokines” [MeSH Terms] OR “cytokines”
[All Fields] OR “cytokine” [All Fields] OR “cytokinic” [All Fields] OR “cytokins” [All
Fields])).
Mesh terms were not used to search the CLSR.
2.3. Study Selection
Two reviewers (RMB and MLM) independently reviewed the titles, abstracts and
full texts for their potential inclusion against the eligibility criteria. Any disagreement
was resolved by discussion with a third reviewer (SC). In cases where information about
a study’s eligibility was limited or incomplete (for instance, when only an abstract was
accessible), the authors of the study were contacted to request the full text or further details.
2.4. Data Extraction, Coding and Analysis
Two authors (MBR and LMM) collected data from all included articles using a pre-
tested form and individuated duplicates, and prepared the flow-chart of excluded and
included studies (Figure 1). SC and CA independently verified the entire process.
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2.6. Dosage of Nutraceuticals
Data were extracted from each trial of the included systematic reviews/meta-analyses,
and they were tabulated according to the results of each trial. We did not tabulate vitamin
D dosage due to the great heterogeneity among trials.
3. Results
No SR regarding the four compounds was of low quality.
The punctual evaluation is reported in the Supplementary Materials.
Regarding vitamin D (Table 1), several SRs were taken into consideration, and they
were heterogenous in different aspects: patient characteristics, type of treatment, end-points
and measured variables.
However, this heterogeneity enriched the final analysis. Nine SRs were included,
with a follow-up duration between 1,5 month and 3 years. The diabetic patients were
mostly represented, but different categories of patients were considered, including those
affected by HIV, obese, elderly or featuring a high cardiovascular risk. Six out of nine
SRs demonstrated a clear efficacy of CRP reduction. Only one SR showed a reduction in
interleukin-6 (IL6).
Table 2 shows the variable dosages used in each study, but an average of 50.000 units
of ergocalciferol monthly were administered to patients.
Regarding vitamin C (Table 3), four SRs showed an effective action on the endothelial
function and CRP reduction with an intervention duration between 1 day and 52 weeks.
The diabetic patients, subjects with chronic diseases and adult participants aged 18 years
and older were considered. Two out of four SRs proved to be effective in reducing CRP
levels. The other two SRs showed beneficial effects on endothelial function.
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Table 1. Vitamin D: characteristics of the included systematic reviews.
Study Omid Asbaghia(2019) [11]
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Table 2. Vitamin D: summary of the principal characteristics of the included systematic reviews.
Pharmaceutical Drug Dose Follow-Up Efficacy Yes Efficacy No Study
Vitamin D1 e D2
Paricalcitol 400 IU day 3 months CRP Mohsen Mazidi(2018) [15]
Ergocalciferol 50.000 IU/ month 12 weeks–6 months CRP Mohsen Mazidi(2018) [15]
Vitamin D3 Cholecalciferol
200–6.000 IU/day









4000 IU/week 8 weeks FMD *, CRP, IL-6e TNF-α
Tari Agbalalah
(2017) [17]
4000 IU/day 24 weeks hs-CRP ** Neng Chen (2014)[19]
≤4000 IU/day >12 weeks CRP TNF-α e IL6 Yanting Yu (2018)[14]
* FMD = flow-mediated dilation (endothelial function parameters). ** hs-CRP = circulating high-sensitivity C-reactive protein.
Table 3. Vitamin C: characteristics of the included systematic reviews.
Scheme 2019. Maryam Safabakhsh(2019) [20]
Sedagh Jafamejad (2018)
[21]
Ammar W. Ashor (2015)
[22]
Ammar W. Ashor (2014)
[23]
Databases searched
PubMed, Scopus, ISI Web
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Results
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mg/d) (SMD: 0·25, 95%
CI 0·02, 0·49, P 14 0·043)
A beneficial effect of
vitamin C on endothelial
function was found (SMD:





have a significant effect










One or two grams of vitamin C per day resulted in the most applicable posology to
increase the efficacy of CRP reduction (Table 4).
Table 5 shows the characteristics of the included systematic reviews of melatonin. Two
SRs showed an effective action of this hormone in terms of reduction in IL-6, TNF-alpha
and CRP. The follow-up duration ranged between 4 months and 60 weeks. The two studies
considered subjects with chronic diseases and individuals affected by metabolic syndrome.
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Table 4. Vitamin C: summary of the principal characteristics of the included systematic reviews.
Administration Dose Follow-Up Endpoint Efficacy Study
Intravenous
250 mg/day 8 weeks CPR Yes Biniaz 2014 [24]
300 mg/day 24 weeks CPR Yes Attallah 2006 [25]
Oral
1 g/day 10 days EF * Yes De Marchi 2012 [26]
1 g/day 4 days CRP Yes Colby 2011 [27]
1 g/day 4 weeks CRP Yes Modi 2014 [28]
2 g/day 4 weeks EF * Yes Antoniades 2004 [29]Tousoulis 2007 [30]
* Endothelial function (EF) measured by either forearm blood flow (FBF) or flow mediated dilation (FMD).
Table 5. Melatonin: characteristics of the included systematic reviews.
Zarezadeh M (2019) [31] Akbari M (2018) [32]
Databases searched SCOPUS, PubMed, Cochrane Library,Embase, Google Scholar
Cochrane Library, EMBASE, PubMed, and
Web of Science
Articles included 13 6
Type of patients analyzed Patients with chronic diseases Patients with metabolic syndrome
Posology 3 to 25 mg/day 6 to 10 mg/day
Intervention duration range From 4 to 60 weeks From 4 weeks to 14 months
Endpoint
To evaluate the effect of supplementation
with melatonin on inflammatory biomarker
levels
To evaluate the effect of supplementation
with melatonin on inflammatory markers




decreased TNF-α and IL-6 levels
[(WMD = −2.24 pg/mL; 95% CI −3.45,
−1.03; p < 0.001; I2 = 96.7%, Pheterogeneity <
0.001) and (WMD = −30.25 pg/mL; 95% CI
−41.45, −19.06; p < 0.001, 2I = 99.0%;
Pheterogeneity < 0.001)], respectively. The
effect of melatonin on CRP levels was
marginal.
Melatonin supplementation significantly
reduced C-reactive protein (SMD = −1.80;
95% CI −3.27, −0.32; p = 0.01; I2: 95.2) and
interleukin 6 (IL-6) concentrations
(SMD= −2.02; 95% CI −3.57, −0.47; p = 0.01;
I2: 91.2) among patients with MetS and




reduced TNF-α and IL-6 levels.
The supplementation with melatonin
improved the levels of TNF-α and IL-6 more
efficiently in studies, which were conducted
for ≥ 12 weeks and at a dosage ≥ 10 mg/day.
The promising effect of melatonin
administration on reducing CRP and IL-6
among patients with metabolic syndrome
and related disorders.
From the analysis of the included trials, a variety of employed dosages emerge
(Table 6); a daily dose from 5 to 25 mg daily has been reported, with similar efficacy.
Finally, we found only one SR of zinc supplementation summarizing 8 RCTs (Table 7).
The intervention duration ranged between 6 and 25 weeks. The hemodialysis patients were
considered.
Three RCTs had a positive effect on CRP reduction using 50 mg of elemental zinc daily
(Table 8).
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Table 6. Melatonin: summary of the principal characteristics of the included systematic reviews.
Administration Dose Follow-Up Endpoint Efficacy Study
Oral
25 mg/day 26 weeks TNF and IL-6 Yes SanchezLopez A (2018) [33]












TNF and IL-6 Yes
Forest CM (2007) [38]
Celinski et al. (2014) [39]
Cichoz-Lach et al. (2010) [40]
6 mg/day 6 weeks TNF and IL-6 Yes Mesri Alamdari (2015) [41]
5 mg/day 52 weeks CPR Yes Chojnacki C (2011) [42]
Table 7. Zinc: characteristics of the included systematic reviews.
Mousavi SM (2018) [43]
Databases searched PubMed, SCOPUS, and Google Scholar
Articles included 8
Type of patients analyzed Hemodialysis patients
Posology 50 mg/day
Intervention duration range 6–25 weeks
Endpoint Effect of supplementation with zinc on plasmaCRP concentrations in adults
Results
The results of the meta-analysis displayed a significant reduction in circulating CRP
levels (WMD: −1.68 mg/L; 95% CI: −2.4 to −0.9, p =< 0.001) following
supplementation with zinc.
Conclusions Supplementation with zinc markedly reduced plasma CRP concentration
Table 8. Dose finding according to single trial results for zinc.
Administration Dose Follow-Up Endpoint Efficacy Study









Pathophysiological basis of nutraceutical supplementation during the COVID-19
pandemic.
4.1. Vitamin D
Recently, the use of cholecalciferol was proposed as a beneficial measure to reduce
the risk of COVID-19, in order to manage the pro-inflammatory milieu [47], and to reduce
virus-induced iron dysmetabolism [48]. Literature data show a scenario of a world epi-
demic of cholecalciferol deficiency [49], which reaches 80% in elderly people, who have
been shown to suffer from a higher COVID-19 mortality rate [50]. The intensity of the host
immune/inflammatory response has repercussions on the clinical severity and mortality
risk associated with viral diseases such as COVID-19, and this factor could be influenced
by vitamin D deficiency. Due to the low (20%) supply of cholecalciferol through dietary
consumption, the supplementation of this pro-hormone has been suggested as beneficial
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in most chronic degenerative diseases. Specifically, active form calcitriol, a secosteroid
hormone, can exert immuno-modulatory/anti-inflammatory activities, playing a role in the
regulation of both innate and adaptive immunity; hence, in the COVID-19-related so-called
“Cytokine storm”, it is considered to be caused by the activation of the innate immune
system and with an excessively increased activation of the adaptive immunity [51,52]. With
regard to innate immunity, calcitriol can inhibit inflammatory T cell cytokines and Toll-like
receptors present on monocytes. Moreover, high doses of calcitriol supplementation result
in a significant reduction in IL-6 [53]. With regard to adaptive immunity, vitamin D also
reduces excessive proliferation and immunoglobulin production in B cells; furthermore,
it may suppress the differentiation of B cells into plasma cells [54]. Cholecalciferol can
reduce the risk of the common viral influenza enhancing the epithelium physical barrier
mechanism, as well as through the modulation of native and adaptive immunity [55]. In
addition, vitamin D is related to the preservation of adhesion junctions, tight and gap
junctions between epithelial cells, and their destruction represents the pathogenic mecha-
nism of viral upper respiratory tract infection [56,57]. Concerning COVID-19, it has been
hypothesized that the correction of vitamin deficiency suppresses CD26/DDP4, one of the
adhesion molecules through which the COVID-19 virus and COVID-MERS virus enter into
host cells [58–60]. Calcitriol could also directly affect SARS-CoV-2 infection through the
anti-microbial cathelicidin family of peptides, particularly LL-37 [18]. This peptide may
induce a viral membrane disruption via electrostatic interactions on the lipid envelopes
of viruses [18,19,61,62]. Cardiovascular thrombotic events have been associated with the
later stages of COVID-19, together with a high prevalence of pulmonary embolism, dis-
seminated intravascular coagulation, liver, myocardial and renal failure [63,64]. Calcitriol
was proven to exert some anticoagulant effects by upregulating the expression of anticoag-
ulant thrombomodulin and downregulating the expression of critical coagulation factor
in monocytes [65–67]. This virus-induced prothrombotic state is worsened in the case of
heme release in the blood stream, which results in an upregulation of NLRP3 inflamma-
some [68,69]. Finally, it can enhance the expression of antioxidant-related genes [26], and
increase the production of glutathione, thereby avoiding the use of ascorbic acid (vitamin
C), which results in an antimicrobial activity [70–72], reducing the production of free radi-
cals involved in inflammation which contribute to the pulmonary damage leading to the
development of acute respiratory distress syndrome (ARDS) [70]. Moreover, vitamin D
plays a crucial role in the reduction in proinflammatory cytokines, such as TNFα and IFNγ,
involved in the pathogenesis of ARDS through the stimulation of Th2 and inhibition of
Th1 [73–75]. Recently, a retrospective study has evaluated the clinical outcomes of 36 out of
91 COVID-19 patients receiving in-hospital high-dose cholecalciferol. During a follow-up
period of approximately two weeks, logistic regression statistical analysis indicated that
the positive effect of high-dose cholecalciferol on the combined endpoint was significantly
augmented with growing comorbidity burden [76]. Moreover, the intermediate form of
vitamin D Calcifediol was proposed as an additional treatment in COVID-19 patients, as
it could significantly reduce the need for ICU treatment [77]. A recent systematic review
and meta-analysis showed that low vitamin D serum levels were significantly associated
with a higher risk of COVID-19 infection [78]. Regarding the severity of the disease, an-
other systematic review highlights that subjects affected by severe COVID-19 present 65%
more vitamin D deficiency in comparison to individuals affected by mild COVID-19. In
addition, vitamin D deficiency was related to increased hospitalization and mortality from
COVID-19 [79].
4.2. Vitamin C
The biomedical literature supports the role of ascorbic acid (AA) (vitamin C) in immu-
nity regulation, anti-infective and anti-NLRP3 (namely, cytokine storm) activity [80–84]. In
fact, this essential compound intervenes in a number of fundamental biochemical pathways
of cell metabolism, including mitochondria functionality. These organelles undergo a high
degree of oxidative stress and mitophagy during COVID-19 degenerative processes [85].
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Vitamin C was shown to prevent mitochondrial membrane depolarization and to combat
mitochondrial DNA oxidative stress and cell toxicity, thus regulating fission and fusion
processes [86,87]. Of interest, in the context of COVID-19-related hypoxia, AA interacts
with hemoglobin to maintain heme iron in ferrous state, which is the only form to bind oxy-
gen [88]. This exclusive beneficial activity on hemoglobin metabolism is best achieved by
combining the supplementation of oral (L-AA) and intravenous AA [48,89,90] Overall, clin-
ical data have previously highlighted a significant role for AA among patients in ICU, with
sepsis, pneumonia, multiorgan failure and ARDS [91]. Similarly, vitamin C immunomod-
ulatory, anti-viral and anti-inflammatory properties have been repeatedly demonstrated
in infective diseases [72,80,92,93]. The combination of these beneficial biochemical fea-
tures has led several centers to assess high-dose AA supplementation as a complementary
therapy in COVID-19 patients [91,94,95]. A few preliminary clinical studies on vitamin
C in critical COVID-19 patients have shown some improvements in the oxygenation and
interleukin-6 level, though a lower benefit for the mortality rate has been reported [96–98].
Conversely, a more pronounced effect of vitamin C in combination with quercetin and
bromelain seems to be effective, in terms of the prevention of COVID-19 infection in health-
workers [99]. Ongoing clinical trials will likely provide more evidence on the possible
efficacy of vitamin C in COVID-19 patients. A randomized clinical trial is analyzing the
efficacy and safety of high-dose vitamin C in combination with Chinese medicine in the
treatment of moderate and severe COVID-19 [100]. An uncontrolled longitudinal study is
attempting to evaluate the efficacy and safety of 10 g of vitamin C intravenously in addition
to conventional therapy in hospitalized patients with COVID-19 [101].
4.3. Melatonin
Melatonin (N-acetyl-5-methoxytryptamine) is a multifunctional hormone which is
secreted mostly by the pineal gland and maximally at nighttime; [102] its secretion is ex-
tremely high in infants and adolescents, much lower in the elderly. Basically, this molecule
helps to regulate many other hormones and maintains the body’s circadian rhythm. Mela-
tonin is significantly involved in the complex network of psycho-neuroendocrine immunol-
ogy (PNEI), stress management and aging mechanisms [103]; furthermore, this compound
interacts with cortisol and with a series of immunity and inflammasome pathways, which
have been shown to derange in COVID-19 [104]. This molecule has been repeatedly con-
sidered a potentially useful compound in COVID-19 patients [48,105–107]. In fact, in these
cases, it may reduce the documented extremely high mitochondria oxidative stress, namely,
in lung cells [108], while conferring a general antioxidant action [42]. Melatonin was
also recognized as a relevant modulator of innate and adaptive immune reactions [109]
and specifically of the inflammasome NLRP3 [110,111], the latter being a hyperactivated
pathway in COVID-19 patients, contributing to the so-called “cytokine storm”. This inflam-
masome downregulation also results in a reduction in pulmonary hypertension, which
typically occurs in the critical stages during Sars-Cov-2 infection [112]. Lastly, melatonin is
known to interact with CD147, a favorite Sars-Cov-2 cell receptor which is diffused in cell
walls, erythrocyte and endothelium specifically. This specific feature has been regarded as a
protective mechanism against a few pathologic pathways which may occur during COVID-
19, such as hemoglobin denaturation, iron accumulation, hypoxia, cardiomyocytes injury
and hypercoagulability [104,106,113]. Very preliminary clinical data correlate the better
survival rate of COVID-19 intubated patients with melatonin exposure [114]; similarly, a
small randomized clinical trial has shown a statistically significant improvement in clinical
and instrumental findings in a group of patients treated additionally with melatonin, with
a more rapid hospital discharge and return to baseline health [115]. A deregulation of
tryptophan (precursor of melatonin) production has been demonstrated in COVID-19,
which led a few authors to postulate the need of a greater supplementation with this
hormone [116]. Of great interest, a recent multidrug repurposing study on 26,779 subjects
affected by COVID-19 elucidated that higher melatonin levels were significantly associ-
ated with a 28% and 52% reduced likelihood of a SARS-CoV-2 infection in the general
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population and in African Americans, respectively [117]. The combination of the potential
and demonstrated beneficial activities of melatonin, which is currently being investigated
in a series of specific clinical trials, may pave the way to a greater employment of this
compound in this pandemic [118].
4.4. Zinc
The transition metal zinc (Zn), after iron, is the second most abundant trace metal in
the human body, and it is essential for multiple cellular functions, including the preser-
vation of immune health, playing a critical role in antiviral immunity. Zn also acts as an
anti-inflammatory agent and functions as an antioxidant, membrane stabilizer. Of interest,
Zn deficiency can lead to immunodeficiency and severe lymphopenia, which is caused
by a corresponding decrease in developing B cells in the bone marrow; furthermore, Zn
potentiates a type-I Interferon (IFN) effect. Marked neutrophilia is detected in severe
COVID-19 patients. Zn gluconate supplementation, inhibiting the NFkB-dependent tran-
scription of inflammatory genes, is able to reduce airway neutrophil infiltration and TNF-α
release. Zn supplementation may be able to reduce inflammatory cytokines (IL-6 and
IL-1β), enhancing the protective type-I IFN response in COVID-19 [119]. Zn inadequacy
and deficiency are predicted to affect about 30% of the world population, in particular
in the elderly; hence, the protective role of zinc supplementation against infection in the
elderly population has been proposed [120]. Zn-deficient individuals experience increased
susceptibility to pathogens, as well as some degree of ageusia and anosmia, emerging
symptoms in COVID-19 patients [121,122]. Interestingly, coronavirus RNA polymerase
activity appears to be inhibited by zinc [123], which could confer this metal a role in pre-
venting coronavirus entry into cells [124] and reducing coronavirus virulency [125]. To
date, scarce and contrasting clinical data on Zn supplementation efficacy on COVID-19
are available and particularly in the outpatient setting. A retrospective study including
141 individuals affected by COVID-19 in the general practice setting showed that zinc in
combination with low-dose hydroxychloroquine was associated with significantly fewer
hospitalizations [126]. On the contrary, in a recent randomized clinical trial of ambula-
tory COVID-19 patients, the administration of high-dose zinc gluconate or zinc gluconate
combined with ascorbic acid did not significantly reduce the durability of symptoms in
comparison with standard of care as well as hospitalizations and deaths [127].
4.5. Evidence
Regarding vitamin D, our review highlights a wide range of SRs, with different
dosages and in different populations. The follow-up was between 1.5 months and 3 years.
Different groups of patients were considered, including patients affected by diabetes, HIV,
obese, elderly or featuring a high cardiovascular risk. Considering that different dosages
of vitamin D (Table 2) showed a similar efficacy in CRP, the intake of 50,000 IU/month
seems to be the proper dosage in terms of advantage and efficacy; moreover, this dose
is in agreement both with the suggested dosage to reduce inflammatory activation and
with the recommendations that advise not to exceed 4000 IU/day, chronically. Regarding
vitamin C, our review identified four high-quality SRs. The intervention duration ranged
from 1 day to 52 weeks Different categories of patients were considered, including diabetic
patients, subjects with chronic diseases and adult participants aged 18 years and older. The
analysis of each single trial (Table 4) suggests that the effective dose is between 1 to 2 g per
day both for CRP and endothelial function. Due to the impracticability of the intravenous
administration within the community medicine policy, oral intake is recommended. With
reference to melatonin, our review highlighted two SRs, both of high quality at AMSTAR
evaluation. The follow-up duration ranged from 4 months to 60 weeks. The two studies
considered subjects with chronic diseases and metabolic syndrome.
Melatonin seems to show good evidence of efficacy regarding the reduction in CRP,
TNF and IL6, with a dosage ranging from 5 to 25 mg/day (Table 7). However, the proper
daily dose should be tailored to the age and clinical conditions of the patent, in order
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to avoid possible adverse effects, such as drowsiness. Literature data on zinc show a
lower strength of evidence, in comparison to the other compounds. We found only one
SR with an intervention duration between 6 and 25 weeks. The hemodialysis patients
were included. The analysis of this single study (Table 8) showed positive results in CRP.
A dosage of 50 mg/day of elemental zinc supplementation was proposed to achieve an
adequate efficacy.
5. Conclusions
According to the selected systematic reviews, vitamin C, vitamin D, melatonin and
zinc nutraceuticals have anti-inflammatory actions. Hence, their large-scale utilization
seems to represent a useful and viable approach during the COVID-19 pandemic. Adequate
doses should be employed, following the most referenced literature data. Of importance,
since no specific drug or other therapeutic or preventive measure has proven to be beneficial
against the progression of COVID-19, this nutraceutical approach could have a role within
a community-based medicine. However, it is to be highlighted that, to date, no systematic
review has demonstrated a specific preventive effectiveness of these compounds in COVID-
19, and many clinical trials are ongoing. In view of this missing evidence, further research is
necessary and desirable to obtain more data on the employment of these natural molecules
as a prevention and/or treatment in the COVID-19 pandemic. Other future clinical trials
should be designed to assess the clinical benefits of each nutraceutical and/or of the
combination of two or more of them. Nevertheless, it might be more useful to implement a
therapeutic supplementation campaign for measuring the effects on the global population.
Observational studies (a design before–after study or cluster quasi-experimental study),
primarily focusing on outcomes such as hospital rates and mortality, would be useful to
preliminarily assess the efficacy of these compounds. Overall, the possible support of the
national health systems would be instrumental to guarantee an adequate provision of these
nutraceuticals to the population. On the basis of the reported data in this review, public
health systems, and subsequently the World Health Organization, could somehow take into
account the possibility to complement current limited preventative measures/interventions
with targeted nutraceutical large-scale administration.
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